{"transactions":[{"id":4636211,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-10-06T20:35:36.000Z","date":"2026-10-02","kind":"exercise","planned":true,"acquired":false,"shares":340,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The stock option vests and is exercisable as to 12.5% of the underlying shares on February 1, 2023, and in 42 substantially equal monthly installments thereafter."}],"balance_after":29104,"derivative":{"exercise_price":52.27,"expiration_date":"2032-08-01","underlying":"Common Stock","underlying_shares":340},"source":{"system":"sec-edgar","filing":"0001950232-26-000003","document":"wk-form4_1791318933.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1950232/000195023226000003/wk-form4_1791318933.xml","form_type":"4"}},{"id":4636210,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Common Stock","published_at":"2026-10-06T20:35:36.000Z","date":"2026-10-02","kind":"sale","planned":true,"acquired":false,"shares":17,"price":307.74,"value":5231.58,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 4, 2026, in accordance with Rule 10b5-1."}],"balance_after":31854,"source":{"system":"sec-edgar","filing":"0001950232-26-000003","document":"wk-form4_1791318933.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1950232/000195023226000003/wk-form4_1791318933.xml","form_type":"4"}},{"id":4636209,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Common Stock","published_at":"2026-10-06T20:35:36.000Z","date":"2026-10-02","kind":"sale","planned":true,"acquired":false,"shares":235,"price":307.1911,"value":72189.9085,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 4, 2026, in accordance with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $306.72 to $307.54. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":31871,"source":{"system":"sec-edgar","filing":"0001950232-26-000003","document":"wk-form4_1791318933.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1950232/000195023226000003/wk-form4_1791318933.xml","form_type":"4"}},{"id":4636208,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Common Stock","published_at":"2026-10-06T20:35:36.000Z","date":"2026-10-02","kind":"sale","planned":true,"acquired":false,"shares":404,"price":306.1834,"value":123698.0936,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 4, 2026, in accordance with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $305.71 to $306.46. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":32106,"source":{"system":"sec-edgar","filing":"0001950232-26-000003","document":"wk-form4_1791318933.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1950232/000195023226000003/wk-form4_1791318933.xml","form_type":"4"}},{"id":4636207,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Common Stock","published_at":"2026-10-06T20:35:36.000Z","date":"2026-10-02","kind":"sale","planned":true,"acquired":false,"shares":1535,"price":304.5154,"value":467431.139,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 4, 2026, in accordance with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $304.19 to $305.01. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":32510,"source":{"system":"sec-edgar","filing":"0001950232-26-000003","document":"wk-form4_1791318933.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1950232/000195023226000003/wk-form4_1791318933.xml","form_type":"4"}},{"id":4636206,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Common Stock","published_at":"2026-10-06T20:35:36.000Z","date":"2026-10-02","kind":"sale","planned":true,"acquired":false,"shares":1976,"price":303.5444,"value":599803.7344,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 4, 2026, in accordance with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $303.14 to $304.12. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":34045,"source":{"system":"sec-edgar","filing":"0001950232-26-000003","document":"wk-form4_1791318933.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1950232/000195023226000003/wk-form4_1791318933.xml","form_type":"4"}},{"id":4636205,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Common Stock","published_at":"2026-10-06T20:35:36.000Z","date":"2026-10-02","kind":"sale","planned":true,"acquired":false,"shares":833,"price":302.5107,"value":251991.4131,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 4, 2026, in accordance with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $302.14 to $303.06. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":36021,"source":{"system":"sec-edgar","filing":"0001950232-26-000003","document":"wk-form4_1791318933.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1950232/000195023226000003/wk-form4_1791318933.xml","form_type":"4"}},{"id":4636204,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Common Stock","published_at":"2026-10-06T20:35:36.000Z","date":"2026-10-02","kind":"exercise","planned":true,"acquired":true,"shares":340,"price":52.27,"value":17771.8,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 4, 2026, in accordance with Rule 10b5-1."}],"balance_after":36854,"source":{"system":"sec-edgar","filing":"0001950232-26-000003","document":"wk-form4_1791318933.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1950232/000195023226000003/wk-form4_1791318933.xml","form_type":"4"}},{"id":4626330,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":40268,"kind":"person","name":"Zimmermann Martine","position":1,"cik":"0001994049","reported_name":"Zimmermann Martine","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-24T21:22:25.000Z","date":"2026-09-22","kind":"tax_withholding","planned":false,"acquired":false,"shares":115,"price":298.5,"value":34327.5,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of restricted stock units."}],"balance_after":3782,"source":{"system":"sec-edgar","filing":"0002001011-26-000142","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1994049/000200101126000142/edgardoc.xml","form_type":"4"}},{"id":4617121,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":40268,"kind":"person","name":"Zimmermann Martine","position":1,"cik":"0001994049","reported_name":"Zimmermann Martine","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-14T20:59:28.000Z","date":"2026-09-10","kind":"sale","planned":false,"acquired":false,"shares":1200,"price":285,"value":342000.0,"ownership":{"direct":true},"balance_after":3897,"source":{"system":"sec-edgar","filing":"0002001011-26-000140","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1994049/000200101126000140/edgardoc.xml","form_type":"4"}},{"id":3608251,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Common Stock","published_at":"2026-09-08T22:34:14.000Z","date":"2026-09-03","kind":"sale","planned":true,"acquired":false,"shares":400,"price":288.9792,"value":115591.68,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 04, 2026, in accordance with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $288.5500 to $289.4300. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":36514,"source":{"system":"sec-edgar","filing":"0002001011-26-000137","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1950232/000200101126000137/edgardoc.xml","form_type":"4"}},{"id":3608250,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Common Stock","published_at":"2026-09-08T22:34:14.000Z","date":"2026-09-03","kind":"sale","planned":true,"acquired":false,"shares":385,"price":287.5253,"value":110697.2405,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 04, 2026, in accordance with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $287.0500 to $287.6600. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":36914,"source":{"system":"sec-edgar","filing":"0002001011-26-000137","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1950232/000200101126000137/edgardoc.xml","form_type":"4"}},{"id":3608249,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Common Stock","published_at":"2026-09-08T22:34:14.000Z","date":"2026-09-03","kind":"sale","planned":true,"acquired":false,"shares":2115,"price":286.3589,"value":605649.0735,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 04, 2026, in accordance with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $285.8000 to $286.7700. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":37299,"source":{"system":"sec-edgar","filing":"0002001011-26-000137","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1950232/000200101126000137/edgardoc.xml","form_type":"4"}},{"id":3608248,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Common Stock","published_at":"2026-09-08T22:34:14.000Z","date":"2026-09-03","kind":"sale","planned":true,"acquired":false,"shares":1800,"price":285.1671,"value":513300.78,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 04, 2026, in accordance with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $284.7500 to $285.7000. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":39414,"source":{"system":"sec-edgar","filing":"0002001011-26-000137","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1950232/000200101126000137/edgardoc.xml","form_type":"4"}},{"id":3608247,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Common Stock","published_at":"2026-09-08T22:34:14.000Z","date":"2026-09-03","kind":"sale","planned":true,"acquired":false,"shares":300,"price":283.9854,"value":85195.62,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 04, 2026, in accordance with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $283.4300 to $284.1550. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":41214,"source":{"system":"sec-edgar","filing":"0002001011-26-000137","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1950232/000200101126000137/edgardoc.xml","form_type":"4"}},{"id":687433,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23538,"kind":"person","name":"Espinoza Octavio","position":1,"cik":"0001905248","reported_name":"Espinoza Octavio","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2026-08-14T21:05:08.000Z","date":"2026-08-12","kind":"exercise","planned":true,"acquired":false,"shares":2074,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 13, 2026, in accordance with Rule 10b5-1."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The stock option vests and is exercisable as to approximately 16% of the underlying shares on August 1, 2019, approximately 74% of the underlying shares in 28 substantially equal monthly installments beginning on September 1, 2019, and approximately 10% of the underlying shares in 12 substantially equal monthly installments thereafter."}],"balance_after":0,"derivative":{"exercise_price":70.04,"expiration_date":"2029-02-01","underlying":"Common Stock","underlying_shares":2074},"source":{"system":"sec-edgar","filing":"0002001011-26-000115","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000115/edgardoc.xml","form_type":"4"}},{"id":687432,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23538,"kind":"person","name":"Espinoza Octavio","position":1,"cik":"0001905248","reported_name":"Espinoza Octavio","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2026-08-14T21:05:08.000Z","date":"2026-08-12","kind":"exercise","planned":true,"acquired":false,"shares":3348,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 13, 2026, in accordance with Rule 10b5-1."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The stock option vests and is exercisable as to approximately 13% of the underlying shares on August 11, 2019, and the remaining of the underlying shares in 40 substantially equal monthly installments thereafter."}],"balance_after":0,"derivative":{"exercise_price":68.74,"expiration_date":"2029-02-11","underlying":"Common Stock","underlying_shares":3348},"source":{"system":"sec-edgar","filing":"0002001011-26-000115","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000115/edgardoc.xml","form_type":"4"}},{"id":687431,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23538,"kind":"person","name":"Espinoza Octavio","position":1,"cik":"0001905248","reported_name":"Espinoza Octavio","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2026-08-14T21:05:08.000Z","date":"2026-08-12","kind":"exercise","planned":true,"acquired":false,"shares":16179,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 13, 2026, in accordance with Rule 10b5-1."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The stock option vests and is exercisable as to approximately 14% of the underlying shares on August 5, 2022, approximately 64% of the underlying shares in 28 substantially equal monthly installments beginning on September 5, 2022, and approximately 22% of the underlying shares in 12 substantially equal monthly installments thereafter."}],"balance_after":0,"derivative":{"exercise_price":52.84,"expiration_date":"2032-05-05","underlying":"Common Stock","underlying_shares":16179},"source":{"system":"sec-edgar","filing":"0002001011-26-000115","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000115/edgardoc.xml","form_type":"4"}},{"id":687430,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23538,"kind":"person","name":"Espinoza Octavio","position":1,"cik":"0001905248","reported_name":"Espinoza Octavio","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-08-14T21:05:08.000Z","date":"2026-08-12","kind":"exercise","planned":true,"acquired":false,"shares":7171,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 13, 2026, in accordance with Rule 10b5-1."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The stock option vests and is exercisable as to approximately 14% of the underlying shares on April 1, 2021, approximately 73% of the underlying shares in 32 substantially equal monthly installments on May 5, 2021, and approximately 13% of the underlying shares in 10 substantially equal monthly installments thereafter."}],"balance_after":0,"derivative":{"exercise_price":57.22,"expiration_date":"2030-10-01","underlying":"Common Stock","underlying_shares":7171},"source":{"system":"sec-edgar","filing":"0002001011-26-000115","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000115/edgardoc.xml","form_type":"4"}},{"id":687429,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23538,"kind":"person","name":"Espinoza Octavio","position":1,"cik":"0001905248","reported_name":"Espinoza Octavio","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-08-14T21:05:08.000Z","date":"2026-08-12","kind":"exercise","planned":true,"acquired":false,"shares":2869,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 13, 2026, in accordance with Rule 10b5-1."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The original grant of 4,039 stock options vests and is exercisable as to approximately 15% of the underlying shares on August 13, 2020, approximately 70% of the underlying shares in 28 substantially equal monthly installments beginning on September 13, 2020, and approximately 15% of the underlying shares in 12 substantially equal monthly installments thereafter."}],"balance_after":0,"derivative":{"exercise_price":55.75,"expiration_date":"2030-02-13","underlying":"Common Stock","underlying_shares":2869},"source":{"system":"sec-edgar","filing":"0002001011-26-000115","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000115/edgardoc.xml","form_type":"4"}},{"id":687428,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23538,"kind":"person","name":"Espinoza Octavio","position":1,"cik":"0001905248","reported_name":"Espinoza Octavio","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-08-14T21:05:08.000Z","date":"2026-08-12","kind":"sale","planned":true,"acquired":false,"shares":31641,"price":292.065,"value":9241228.665,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 13, 2026, in accordance with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $292.0098 to $292.0846. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":27696,"source":{"system":"sec-edgar","filing":"0002001011-26-000115","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000115/edgardoc.xml","form_type":"4"}},{"id":687427,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23538,"kind":"person","name":"Espinoza Octavio","position":1,"cik":"0001905248","reported_name":"Espinoza Octavio","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-08-14T21:05:08.000Z","date":"2026-08-12","kind":"exercise","planned":true,"acquired":true,"shares":3348,"price":68.74,"value":230141.52,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 13, 2026, in accordance with Rule 10b5-1."}],"balance_after":59337,"source":{"system":"sec-edgar","filing":"0002001011-26-000115","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000115/edgardoc.xml","form_type":"4"}},{"id":687426,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23538,"kind":"person","name":"Espinoza Octavio","position":1,"cik":"0001905248","reported_name":"Espinoza Octavio","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-08-14T21:05:08.000Z","date":"2026-08-12","kind":"exercise","planned":true,"acquired":true,"shares":7171,"price":57.22,"value":410324.62,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 13, 2026, in accordance with Rule 10b5-1."}],"balance_after":55989,"source":{"system":"sec-edgar","filing":"0002001011-26-000115","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000115/edgardoc.xml","form_type":"4"}},{"id":687425,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23538,"kind":"person","name":"Espinoza Octavio","position":1,"cik":"0001905248","reported_name":"Espinoza Octavio","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-08-14T21:05:08.000Z","date":"2026-08-12","kind":"exercise","planned":true,"acquired":true,"shares":2869,"price":55.75,"value":159946.75,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 13, 2026, in accordance with Rule 10b5-1."}],"balance_after":48818,"source":{"system":"sec-edgar","filing":"0002001011-26-000115","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000115/edgardoc.xml","form_type":"4"}},{"id":687424,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23538,"kind":"person","name":"Espinoza Octavio","position":1,"cik":"0001905248","reported_name":"Espinoza Octavio","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-08-14T21:05:08.000Z","date":"2026-08-12","kind":"exercise","planned":true,"acquired":true,"shares":2074,"price":70.04,"value":145262.96,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 13, 2026, in accordance with Rule 10b5-1."}],"balance_after":45949,"source":{"system":"sec-edgar","filing":"0002001011-26-000115","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000115/edgardoc.xml","form_type":"4"}},{"id":687423,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23538,"kind":"person","name":"Espinoza Octavio","position":1,"cik":"0001905248","reported_name":"Espinoza Octavio","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-08-14T21:05:08.000Z","date":"2026-08-12","kind":"exercise","planned":true,"acquired":true,"shares":16179,"price":52.84,"value":854898.36,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 13, 2026, in accordance with Rule 10b5-1."}],"balance_after":43875,"source":{"system":"sec-edgar","filing":"0002001011-26-000115","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000115/edgardoc.xml","form_type":"4"}},{"id":687422,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23537,"kind":"person","name":"Haas Jason","position":1,"cik":"0001883821","reported_name":"Haas Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2026-08-14T21:04:53.000Z","date":"2026-08-12","kind":"exercise","planned":false,"acquired":false,"shares":6138,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This Option was previously reported as a Grant of 5,907 shares on June 29, 2022, at an exercise price of $88.48 per share, which becomes exercisable in three successive annual installments upon completion of each calendar year of service beginning on the grant date, but was adjusted pursuant to the OmniAb Inc. separation from the issuer."}],"balance_after":0,"derivative":{"exercise_price":51.56,"expiration_date":"2032-06-29","underlying":"Common Stock","underlying_shares":6138},"source":{"system":"sec-edgar","filing":"0002001011-26-000114","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000114/edgardoc.xml","form_type":"4"}},{"id":687421,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23537,"kind":"person","name":"Haas Jason","position":1,"cik":"0001883821","reported_name":"Haas Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-14T21:04:53.000Z","date":"2026-08-12","kind":"sale","planned":false,"acquired":false,"shares":7138,"price":292.8078,"value":2090062.0764,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $292.5000 to $292.8550. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":3981,"source":{"system":"sec-edgar","filing":"0002001011-26-000114","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000114/edgardoc.xml","form_type":"4"}},{"id":687420,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23537,"kind":"person","name":"Haas Jason","position":1,"cik":"0001883821","reported_name":"Haas Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-14T21:04:53.000Z","date":"2026-08-12","kind":"exercise","planned":false,"acquired":true,"shares":6138,"price":51.56,"value":316475.28,"ownership":{"direct":true},"balance_after":11119,"source":{"system":"sec-edgar","filing":"0002001011-26-000114","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000114/edgardoc.xml","form_type":"4"}},{"id":698020,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-08-04T22:42:58.000Z","date":"2026-08-03","kind":"exercise","planned":true,"acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F12","text":"The stock option vests and is exercisable as to 12.5% of the underlying shares on February 1, 2023, and in 42 substantially equal monthly installments thereafter."}],"balance_after":29444,"derivative":{"exercise_price":52.27,"expiration_date":"2032-08-01","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0002001011-26-000111","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000111/edgardoc.xml","form_type":"4"}},{"id":698019,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Common Stock","published_at":"2026-08-04T22:42:58.000Z","date":"2026-08-03","kind":"sale","planned":true,"acquired":false,"shares":409,"price":292.8191,"value":119763.0119,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F11","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $292.78 to $292.89. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":41514,"source":{"system":"sec-edgar","filing":"0002001011-26-000111","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000111/edgardoc.xml","form_type":"4"}},{"id":698018,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Common Stock","published_at":"2026-08-04T22:42:58.000Z","date":"2026-08-03","kind":"sale","planned":true,"acquired":false,"shares":991,"price":291.7119,"value":289086.4929,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $291.57 to $292.47. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":41923,"source":{"system":"sec-edgar","filing":"0002001011-26-000111","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000111/edgardoc.xml","form_type":"4"}},{"id":698017,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Common Stock","published_at":"2026-08-04T22:42:58.000Z","date":"2026-08-03","kind":"sale","planned":true,"acquired":false,"shares":200,"price":290.6,"value":58120.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $290.48 to $290.72. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":42914,"source":{"system":"sec-edgar","filing":"0002001011-26-000111","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000111/edgardoc.xml","form_type":"4"}},{"id":698016,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Common Stock","published_at":"2026-08-04T22:42:58.000Z","date":"2026-08-03","kind":"sale","planned":true,"acquired":false,"shares":503,"price":289.8022,"value":145770.5066,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $289.33 to $290.18. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":43114,"source":{"system":"sec-edgar","filing":"0002001011-26-000111","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000111/edgardoc.xml","form_type":"4"}},{"id":698015,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Common Stock","published_at":"2026-08-04T22:42:58.000Z","date":"2026-08-03","kind":"sale","planned":true,"acquired":false,"shares":356,"price":288.7496,"value":102794.8576,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $288.32 to $289.20. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":43617,"source":{"system":"sec-edgar","filing":"0002001011-26-000111","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000111/edgardoc.xml","form_type":"4"}},{"id":698014,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Common Stock","published_at":"2026-08-04T22:42:58.000Z","date":"2026-08-03","kind":"sale","planned":true,"acquired":false,"shares":1214,"price":287.7731,"value":349356.5434,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $287.30 to $288.27. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":43973,"source":{"system":"sec-edgar","filing":"0002001011-26-000111","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000111/edgardoc.xml","form_type":"4"}},{"id":698013,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Common Stock","published_at":"2026-08-04T22:42:58.000Z","date":"2026-08-03","kind":"sale","planned":true,"acquired":false,"shares":1032,"price":286.7968,"value":295974.2976,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $286.28 to $287.17. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":45187,"source":{"system":"sec-edgar","filing":"0002001011-26-000111","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000111/edgardoc.xml","form_type":"4"}},{"id":698012,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Common Stock","published_at":"2026-08-04T22:42:58.000Z","date":"2026-08-03","kind":"sale","planned":true,"acquired":false,"shares":157,"price":285.7357,"value":44860.5049,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $285.28 to $285.90. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":46219,"source":{"system":"sec-edgar","filing":"0002001011-26-000111","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000111/edgardoc.xml","form_type":"4"}},{"id":698011,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Common Stock","published_at":"2026-08-04T22:42:58.000Z","date":"2026-08-03","kind":"sale","planned":true,"acquired":false,"shares":33,"price":284.553,"value":9390.249,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $284.28 to $284.58. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":46376,"source":{"system":"sec-edgar","filing":"0002001011-26-000111","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000111/edgardoc.xml","form_type":"4"}},{"id":698010,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Common Stock","published_at":"2026-08-04T22:42:58.000Z","date":"2026-08-03","kind":"sale","planned":true,"acquired":false,"shares":105,"price":284.1375,"value":29834.4375,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $283.24 to $284.23. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":46409,"source":{"system":"sec-edgar","filing":"0002001011-26-000111","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000111/edgardoc.xml","form_type":"4"}},{"id":698009,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Common Stock","published_at":"2026-08-04T22:42:58.000Z","date":"2026-08-03","kind":"exercise","planned":true,"acquired":true,"shares":5000,"price":52.27,"value":261350.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1."}],"balance_after":46514,"source":{"system":"sec-edgar","filing":"0002001011-26-000111","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000111/edgardoc.xml","form_type":"4"}},{"id":716399,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-07-06T21:11:31.000Z","date":"2026-07-01","kind":"exercise","planned":true,"acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"The stock option vests and is exercisable as to 12.5% of the underlying shares on February 1, 2023, and in 42 substantially equal monthly installments thereafter."}],"balance_after":34444,"derivative":{"exercise_price":52.27,"expiration_date":"2032-08-01","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0002001011-26-000108","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000108/edgardoc.xml","form_type":"4"}},{"id":716398,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Common Stock","published_at":"2026-07-06T21:11:31.000Z","date":"2026-07-01","kind":"sale","planned":true,"acquired":false,"shares":600,"price":317.1517,"value":190291.02,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $316.7000 to $317.4300. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":41514,"source":{"system":"sec-edgar","filing":"0002001011-26-000108","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000108/edgardoc.xml","form_type":"4"}},{"id":716397,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Common Stock","published_at":"2026-07-06T21:11:31.000Z","date":"2026-07-01","kind":"sale","planned":true,"acquired":false,"shares":900,"price":315.7775,"value":284199.75,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $315.4400 to $316.2600. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":42114,"source":{"system":"sec-edgar","filing":"0002001011-26-000108","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000108/edgardoc.xml","form_type":"4"}},{"id":716396,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Common Stock","published_at":"2026-07-06T21:11:31.000Z","date":"2026-07-01","kind":"sale","planned":true,"acquired":false,"shares":100,"price":314.5788,"value":31457.88,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $314.3100 to $314.5900. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":43014,"source":{"system":"sec-edgar","filing":"0002001011-26-000108","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000108/edgardoc.xml","form_type":"4"}},{"id":716395,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Common Stock","published_at":"2026-07-06T21:11:31.000Z","date":"2026-07-01","kind":"sale","planned":true,"acquired":false,"shares":700,"price":313.4574,"value":219420.18,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $313.1300 to $314.0100. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":43114,"source":{"system":"sec-edgar","filing":"0002001011-26-000108","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000108/edgardoc.xml","form_type":"4"}},{"id":716394,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Common Stock","published_at":"2026-07-06T21:11:31.000Z","date":"2026-07-01","kind":"sale","planned":true,"acquired":false,"shares":1081,"price":312.2784,"value":337572.9504,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $312.1050 to $312.5300. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":43814,"source":{"system":"sec-edgar","filing":"0002001011-26-000108","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000108/edgardoc.xml","form_type":"4"}},{"id":716393,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Common Stock","published_at":"2026-07-06T21:11:31.000Z","date":"2026-07-01","kind":"sale","planned":true,"acquired":false,"shares":1119,"price":311.72,"value":348814.68,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $311.0900 to $312.0400. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":44895,"source":{"system":"sec-edgar","filing":"0002001011-26-000108","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000108/edgardoc.xml","form_type":"4"}},{"id":716392,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Common Stock","published_at":"2026-07-06T21:11:31.000Z","date":"2026-07-01","kind":"sale","planned":true,"acquired":false,"shares":104,"price":310.2023,"value":32261.0392,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $310.0100 to $310.2100. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":46014,"source":{"system":"sec-edgar","filing":"0002001011-26-000108","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000108/edgardoc.xml","form_type":"4"}},{"id":716391,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Common Stock","published_at":"2026-07-06T21:11:31.000Z","date":"2026-07-01","kind":"sale","planned":true,"acquired":false,"shares":396,"price":308.9886,"value":122359.4856,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $308.6300 to $309.6000. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":46118,"source":{"system":"sec-edgar","filing":"0002001011-26-000108","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000108/edgardoc.xml","form_type":"4"}},{"id":716390,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Common Stock","published_at":"2026-07-06T21:11:31.000Z","date":"2026-07-01","kind":"exercise","planned":true,"acquired":true,"shares":5000,"price":52.27,"value":261350.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1."}],"balance_after":46514,"source":{"system":"sec-edgar","filing":"0002001011-26-000108","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000108/edgardoc.xml","form_type":"4"}},{"id":716389,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Common Stock","published_at":"2026-07-06T21:11:31.000Z","date":"2026-06-30","kind":"other","planned":true,"acquired":true,"shares":132,"price":160.7095,"value":21213.654,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were acquired under the Ligand Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c)."}],"balance_after":41514,"source":{"system":"sec-edgar","filing":"0002001011-26-000108","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000108/edgardoc.xml","form_type":"4"}},{"id":716388,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23538,"kind":"person","name":"Espinoza Octavio","position":1,"cik":"0001905248","reported_name":"Espinoza Octavio","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-07-06T21:11:09.000Z","date":"2026-06-30","kind":"other","planned":false,"acquired":true,"shares":17,"price":160.7095,"value":2732.0615,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were acquired under the Ligand Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c)."}],"balance_after":27696,"source":{"system":"sec-edgar","filing":"0002001011-26-000107","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000107/edgardoc.xml","form_type":"4"}},{"id":716387,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":32389,"kind":"person","name":"Davis Todd C","position":1,"cik":"0001392029","reported_name":"Davis Todd C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-07-06T21:10:32.000Z","date":"2026-06-30","kind":"other","planned":false,"acquired":true,"shares":132,"price":160.7095,"value":21213.654,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were acquired under the Ligand Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c)."}],"balance_after":199513,"source":{"system":"sec-edgar","filing":"0002001011-26-000106","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000106/edgardoc.xml","form_type":"4"}},{"id":732835,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":37006,"kind":"person","name":"Sabba Stephen L","position":1,"cik":"0001442372","reported_name":"Sabba Stephen L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2026-06-18T12:37:48.000Z","date":"2026-06-16","kind":"exercise","planned":false,"acquired":false,"shares":2145,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F2","text":"These securities, as represented in Column 5, were acquired by a grant of 2,456 shares approved by the Board of Directors of the Company at the 2017 Meeting, as previously reported on the Reporting Person's Form 4, dated 30 May 2017. That grant vested in full on the first anniversary of the grant date or immediately (x) upon a change in control or a hostile takeover of the Company or (y) the death or permanent disability of the grantee if still serving at that time. The original grant was adjusted to 2,145 shares and the exercise price adjusted to $66.13 pursuant to the OmniAb Inc. separation from the Company."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These securities, as represented in Column 5, were acquired by a grant of 2,456 shares approved by the Board of Directors of the Company at the 2017 Meeting, as previously reported on the Reporting Person's Form 4, dated 30 May 2017. That grant vested in full on the first anniversary of the grant date or immediately (x) upon a change in control or a hostile takeover of the Company or (y) the death or permanent disability of the grantee if still serving at that time. The original grant was adjusted to 2,145 shares and the exercise price adjusted to $66.13 pursuant to the OmniAb Inc. separation from the Company."}],"balance_after":0,"derivative":{"exercise_price":66.13,"expiration_date":"2027-05-25","underlying":"Common Stock","underlying_shares":2145},"source":{"system":"sec-edgar","filing":"0001104659-26-075456","document":"tm2618247-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/886163/000110465926075456/tm2618247-1_4seq1.xml","form_type":"4"}},{"id":732834,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":37006,"kind":"person","name":"Sabba Stephen L","position":1,"cik":"0001442372","reported_name":"Sabba Stephen L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-18T12:37:48.000Z","date":"2026-06-16","kind":"sale","planned":false,"acquired":false,"shares":2145,"price":254,"value":544830.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"These securities, as represented in Column 5, include the grant of 836 restricted shares approved by the Board of Directors of the Company at the 2026 Meeting held 5 June 2026, which shares were previously reported on a Form 4 for this Reporting Person dated 9 June 2026."}],"balance_after":33629,"source":{"system":"sec-edgar","filing":"0001104659-26-075456","document":"tm2618247-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/886163/000110465926075456/tm2618247-1_4seq1.xml","form_type":"4"}},{"id":732833,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":37006,"kind":"person","name":"Sabba Stephen L","position":1,"cik":"0001442372","reported_name":"Sabba Stephen L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-18T12:37:48.000Z","date":"2026-06-16","kind":"exercise","planned":false,"acquired":true,"shares":2145,"price":66.13,"value":141848.85,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"These securities, as represented in Column 5, include the grant of 836 restricted shares approved by the Board of Directors of the Company at the 2026 Meeting held 5 June 2026, which shares were previously reported on a Form 4 for this Reporting Person dated 9 June 2026."}],"balance_after":35774,"source":{"system":"sec-edgar","filing":"0001104659-26-075456","document":"tm2618247-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000110465926075456/tm2618247-1_4seq1.xml","form_type":"4"}},{"id":738588,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23537,"kind":"person","name":"Haas Jason","position":1,"cik":"0001883821","reported_name":"Haas Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2026-06-16T01:06:58.000Z","date":"2026-06-12","kind":"exercise","planned":false,"acquired":false,"shares":1000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This Option was previously reported as a Grant of 5,907 shares on June 29, 2022, at an exercise price of $88.48 per share, which becomes exercisable in three successive annual installments upon completion of each calendar year of service beginning on the grant date, but was adjusted pursuant to the OmniAb Inc. separation from the issuer."}],"balance_after":6138,"derivative":{"exercise_price":51.56,"expiration_date":"2032-06-29","underlying":"Common Stock","underlying_shares":1000},"source":{"system":"sec-edgar","filing":"0002001011-26-000104","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000104/edgardoc.xml","form_type":"4"}},{"id":738587,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23537,"kind":"person","name":"Haas Jason","position":1,"cik":"0001883821","reported_name":"Haas Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2026-06-16T01:06:58.000Z","date":"2026-06-12","kind":"exercise","planned":false,"acquired":false,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This Option was previously reported as a Grant of 5,907 shares on June 29, 2022, at an exercise price of $88.48 per share, which becomes exercisable in three successive annual installments upon completion of each calendar year of service beginning on the grant date, but was adjusted pursuant to the OmniAb Inc. separation from the issuer."}],"balance_after":7138,"derivative":{"exercise_price":51.56,"expiration_date":"2032-06-29","underlying":"Common Stock","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0002001011-26-000104","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000104/edgardoc.xml","form_type":"4"}},{"id":738586,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23537,"kind":"person","name":"Haas Jason","position":1,"cik":"0001883821","reported_name":"Haas Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-16T01:06:58.000Z","date":"2026-06-12","kind":"sale","planned":false,"acquired":false,"shares":3461,"price":256.0781,"value":886286.3041,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $256.0000 to $256.5100. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":4981,"source":{"system":"sec-edgar","filing":"0002001011-26-000104","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000104/edgardoc.xml","form_type":"4"}},{"id":738585,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23537,"kind":"person","name":"Haas Jason","position":1,"cik":"0001883821","reported_name":"Haas Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-16T01:06:58.000Z","date":"2026-06-12","kind":"sale","planned":false,"acquired":false,"shares":3000,"price":255.0113,"value":765033.9,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $255.0000 to $255.2900. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":8442,"source":{"system":"sec-edgar","filing":"0002001011-26-000104","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000104/edgardoc.xml","form_type":"4"}},{"id":738584,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23537,"kind":"person","name":"Haas Jason","position":1,"cik":"0001883821","reported_name":"Haas Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-16T01:06:58.000Z","date":"2026-06-12","kind":"exercise","planned":false,"acquired":true,"shares":1000,"price":51.56,"value":51560.0,"ownership":{"direct":true},"balance_after":11442,"source":{"system":"sec-edgar","filing":"0002001011-26-000104","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000104/edgardoc.xml","form_type":"4"}},{"id":738583,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23537,"kind":"person","name":"Haas Jason","position":1,"cik":"0001883821","reported_name":"Haas Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-16T01:06:58.000Z","date":"2026-06-12","kind":"exercise","planned":false,"acquired":true,"shares":3000,"price":51.56,"value":154680.0,"ownership":{"direct":true},"balance_after":10442,"source":{"system":"sec-edgar","filing":"0002001011-26-000104","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000104/edgardoc.xml","form_type":"4"}},{"id":740746,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":35404,"kind":"person","name":"Aryeh Jason","position":1,"cik":"0001376960","reported_name":"Aryeh Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2026-06-12T21:27:26.000Z","date":"2026-06-05","kind":"grant","planned":false,"acquired":true,"shares":2938,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 5, 2026. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant."}],"balance_after":2938,"derivative":{"exercise_price":237,"expiration_date":"2036-06-05","underlying":"Common Stock","underlying_shares":2938},"source":{"system":"sec-edgar","filing":"0002001011-26-000103","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000103/edgardoc.xml","form_type":"4"}},{"id":740745,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":35404,"kind":"person","name":"Aryeh Jason","position":1,"cik":"0001376960","reported_name":"Aryeh Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-12T21:27:26.000Z","date":"2026-06-11","kind":"sale","planned":false,"acquired":false,"shares":4500,"price":250,"value":1125000.0,"ownership":{"direct":true},"balance_after":102580,"source":{"system":"sec-edgar","filing":"0002001011-26-000103","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000103/edgardoc.xml","form_type":"4"}},{"id":740744,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":35404,"kind":"person","name":"Aryeh Jason","position":1,"cik":"0001376960","reported_name":"Aryeh Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-12T21:27:26.000Z","date":"2026-06-10","kind":"sale","planned":false,"acquired":false,"shares":500,"price":250,"value":125000.0,"ownership":{"direct":true},"balance_after":107080,"source":{"system":"sec-edgar","filing":"0002001011-26-000103","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000103/edgardoc.xml","form_type":"4"}},{"id":740743,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":35404,"kind":"person","name":"Aryeh Jason","position":1,"cik":"0001376960","reported_name":"Aryeh Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-12T21:27:26.000Z","date":"2026-06-05","kind":"grant","planned":false,"acquired":true,"shares":836,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 5, 2026. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The total number of shares owned has been reduced by 7,825 shares to reflect a reallocation of the reporting person's shares in accordance with his account records."}],"balance_after":107580,"source":{"system":"sec-edgar","filing":"0002001011-26-000103","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000103/edgardoc.xml","form_type":"4"}},{"id":740742,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":17238,"kind":"person","name":"LAMATTINA JOHN L","position":1,"cik":"0001216074","reported_name":"LAMATTINA JOHN L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-12T21:26:25.000Z","date":"2026-06-10","kind":"sale","planned":false,"acquired":false,"shares":3405,"price":251.6158,"value":856751.799,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $250.9100 to $251.8950. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":26969,"source":{"system":"sec-edgar","filing":"0002001011-26-000102","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000102/edgardoc.xml","form_type":"4"}},{"id":740741,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":17238,"kind":"person","name":"LAMATTINA JOHN L","position":1,"cik":"0001216074","reported_name":"LAMATTINA JOHN L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-12T21:26:25.000Z","date":"2026-06-10","kind":"sale","planned":false,"acquired":false,"shares":697,"price":249.5326,"value":173924.2222,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $249.3400 to $250.2700. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":30374,"source":{"system":"sec-edgar","filing":"0002001011-26-000102","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000102/edgardoc.xml","form_type":"4"}},{"id":740740,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":17238,"kind":"person","name":"LAMATTINA JOHN L","position":1,"cik":"0001216074","reported_name":"LAMATTINA JOHN L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-12T21:26:25.000Z","date":"2026-06-10","kind":"sale","planned":false,"acquired":false,"shares":232,"price":248.1111,"value":57561.7752,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $247.9400 to $248.3350. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":31071,"source":{"system":"sec-edgar","filing":"0002001011-26-000102","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000102/edgardoc.xml","form_type":"4"}},{"id":740739,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":17238,"kind":"person","name":"LAMATTINA JOHN L","position":1,"cik":"0001216074","reported_name":"LAMATTINA JOHN L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-12T21:26:25.000Z","date":"2026-06-10","kind":"sale","planned":false,"acquired":false,"shares":257,"price":247.2237,"value":63536.4909,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $246.6300 to $247.6100. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":31303,"source":{"system":"sec-edgar","filing":"0002001011-26-000102","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000102/edgardoc.xml","form_type":"4"}},{"id":745422,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":40268,"kind":"person","name":"Zimmermann Martine","position":1,"cik":"0001994049","reported_name":"Zimmermann Martine","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2026-06-09T23:42:12.000Z","date":"2026-06-05","kind":"grant","planned":false,"acquired":true,"shares":2938,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 5, 2026. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant."}],"balance_after":2938,"derivative":{"exercise_price":237,"expiration_date":"2036-06-05","underlying":"Common Stock","underlying_shares":2938},"source":{"system":"sec-edgar","filing":"0002001011-26-000101","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000101/edgardoc.xml","form_type":"4"}},{"id":745421,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":40268,"kind":"person","name":"Zimmermann Martine","position":1,"cik":"0001994049","reported_name":"Zimmermann Martine","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-09T23:42:12.000Z","date":"2026-06-05","kind":"tax_withholding","planned":false,"acquired":false,"shares":182,"price":237,"value":43134.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of restricted stock units."}],"balance_after":5097,"source":{"system":"sec-edgar","filing":"0002001011-26-000101","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000101/edgardoc.xml","form_type":"4"}},{"id":745420,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":40268,"kind":"person","name":"Zimmermann Martine","position":1,"cik":"0001994049","reported_name":"Zimmermann Martine","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-09T23:42:12.000Z","date":"2026-06-05","kind":"grant","planned":false,"acquired":true,"shares":836,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 5, 2026. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant."}],"balance_after":5279,"source":{"system":"sec-edgar","filing":"0002001011-26-000101","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000101/edgardoc.xml","form_type":"4"}},{"id":745419,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":37006,"kind":"person","name":"Sabba Stephen L","position":1,"cik":"0001442372","reported_name":"Sabba Stephen L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2026-06-09T23:41:48.000Z","date":"2026-06-05","kind":"grant","planned":false,"acquired":true,"shares":2938,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 5, 2026. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant."}],"balance_after":2938,"derivative":{"exercise_price":237,"expiration_date":"2036-06-05","underlying":"Common Stock","underlying_shares":2938},"source":{"system":"sec-edgar","filing":"0002001011-26-000100","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000100/edgardoc.xml","form_type":"4"}},{"id":745418,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":37006,"kind":"person","name":"Sabba Stephen L","position":1,"cik":"0001442372","reported_name":"Sabba Stephen L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-09T23:41:48.000Z","date":"2026-06-05","kind":"grant","planned":false,"acquired":true,"shares":836,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 5, 2026. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant."}],"balance_after":33629,"source":{"system":"sec-edgar","filing":"0002001011-26-000100","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000100/edgardoc.xml","form_type":"4"}},{"id":745417,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":17238,"kind":"person","name":"LAMATTINA JOHN L","position":1,"cik":"0001216074","reported_name":"LAMATTINA JOHN L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2026-06-09T23:41:02.000Z","date":"2026-06-05","kind":"grant","planned":false,"acquired":true,"shares":2938,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 5, 2026. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant."}],"balance_after":2938,"derivative":{"exercise_price":237,"expiration_date":"2036-06-05","underlying":"Common Stock","underlying_shares":2938},"source":{"system":"sec-edgar","filing":"0002001011-26-000099","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000099/edgardoc.xml","form_type":"4"}},{"id":745416,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":17238,"kind":"person","name":"LAMATTINA JOHN L","position":1,"cik":"0001216074","reported_name":"LAMATTINA JOHN L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-09T23:41:02.000Z","date":"2026-06-05","kind":"grant","planned":false,"acquired":true,"shares":836,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 5, 2026. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant."}],"balance_after":31560,"source":{"system":"sec-edgar","filing":"0002001011-26-000099","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000099/edgardoc.xml","form_type":"4"}},{"id":745415,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":40267,"kind":"person","name":"KOZARICH JOHN W","position":1,"cik":"0001223000","reported_name":"KOZARICH JOHN W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2026-06-09T23:40:20.000Z","date":"2026-06-05","kind":"grant","planned":false,"acquired":true,"shares":2938,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 5, 2026. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant."}],"balance_after":2938,"derivative":{"exercise_price":237,"expiration_date":"2036-06-05","underlying":"Common Stock","underlying_shares":2938},"source":{"system":"sec-edgar","filing":"0002001011-26-000098","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000098/edgardoc.xml","form_type":"4"}},{"id":745414,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":40267,"kind":"person","name":"KOZARICH JOHN W","position":1,"cik":"0001223000","reported_name":"KOZARICH JOHN W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-09T23:40:20.000Z","date":"2026-06-05","kind":"grant","planned":false,"acquired":true,"shares":836,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 5, 2026. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant."}],"balance_after":42622,"source":{"system":"sec-edgar","filing":"0002001011-26-000098","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000098/edgardoc.xml","form_type":"4"}},{"id":745413,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23537,"kind":"person","name":"Haas Jason","position":1,"cik":"0001883821","reported_name":"Haas Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2026-06-09T23:35:49.000Z","date":"2026-06-05","kind":"grant","planned":false,"acquired":true,"shares":2938,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 5, 2026. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant."}],"balance_after":2938,"derivative":{"exercise_price":237,"expiration_date":"2036-06-05","underlying":"Common Stock","underlying_shares":2938},"source":{"system":"sec-edgar","filing":"0002001011-26-000097","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000097/edgardoc.xml","form_type":"4"}},{"id":745412,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23537,"kind":"person","name":"Haas Jason","position":1,"cik":"0001883821","reported_name":"Haas Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-09T23:35:49.000Z","date":"2026-06-05","kind":"grant","planned":false,"acquired":true,"shares":836,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 5, 2026. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant."}],"balance_after":7442,"source":{"system":"sec-edgar","filing":"0002001011-26-000097","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000097/edgardoc.xml","form_type":"4"}},{"id":745410,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":40265,"kind":"person","name":"Gray Nancy Ryan","position":1,"cik":"0001714949","reported_name":"Gray Nancy Ryan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2026-06-09T23:35:33.000Z","date":"2026-06-05","kind":"grant","planned":false,"acquired":true,"shares":2938,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 5, 2026. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant."}],"balance_after":2938,"derivative":{"exercise_price":237,"expiration_date":"2036-06-05","underlying":"Common Stock","underlying_shares":2938},"source":{"system":"sec-edgar","filing":"0002001011-26-000096","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000096/edgardoc.xml","form_type":"4"}},{"id":745409,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":40265,"kind":"person","name":"Gray Nancy Ryan","position":1,"cik":"0001714949","reported_name":"Gray Nancy Ryan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-09T23:35:33.000Z","date":"2026-06-05","kind":"grant","planned":false,"acquired":true,"shares":836,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 5, 2026. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant."}],"balance_after":8930,"source":{"system":"sec-edgar","filing":"0002001011-26-000096","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000096/edgardoc.xml","form_type":"4"}},{"id":755993,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-06-02T22:22:18.000Z","date":"2026-06-01","kind":"exercise","planned":true,"acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The stock option vests and is exercisable as to 12.5% of the underlying shares on February 1, 2023, and in 42 substantially equal monthly installments thereafter."}],"balance_after":39444,"derivative":{"exercise_price":52.27,"expiration_date":"2032-08-01","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0002001011-26-000083","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000083/edgardoc.xml","form_type":"4"}},{"id":755992,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Common Stock","published_at":"2026-06-02T22:22:18.000Z","date":"2026-06-01","kind":"sale","planned":true,"acquired":false,"shares":200,"price":230.41,"value":46082.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1."}],"balance_after":41382,"source":{"system":"sec-edgar","filing":"0002001011-26-000083","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000083/edgardoc.xml","form_type":"4"}},{"id":755991,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Common Stock","published_at":"2026-06-02T22:22:18.000Z","date":"2026-06-01","kind":"sale","planned":true,"acquired":false,"shares":1216,"price":229.4676,"value":279032.6016,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $229.0900 to $230.0000. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":41582,"source":{"system":"sec-edgar","filing":"0002001011-26-000083","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000083/edgardoc.xml","form_type":"4"}},{"id":755990,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Common Stock","published_at":"2026-06-02T22:22:18.000Z","date":"2026-06-01","kind":"sale","planned":true,"acquired":false,"shares":584,"price":228.5738,"value":133487.0992,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $228.0500 to $228.9650. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":42798,"source":{"system":"sec-edgar","filing":"0002001011-26-000083","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000083/edgardoc.xml","form_type":"4"}},{"id":755989,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Common Stock","published_at":"2026-06-02T22:22:18.000Z","date":"2026-06-01","kind":"sale","planned":true,"acquired":false,"shares":400,"price":226.7794,"value":90711.76,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $226.5250 to $227.0100. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":43382,"source":{"system":"sec-edgar","filing":"0002001011-26-000083","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000083/edgardoc.xml","form_type":"4"}},{"id":755988,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Common Stock","published_at":"2026-06-02T22:22:18.000Z","date":"2026-06-01","kind":"sale","planned":true,"acquired":false,"shares":1432,"price":225.9672,"value":323585.0304,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $225.5200 to $226.3700. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":43782,"source":{"system":"sec-edgar","filing":"0002001011-26-000083","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000083/edgardoc.xml","form_type":"4"}},{"id":755987,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Common Stock","published_at":"2026-06-02T22:22:18.000Z","date":"2026-06-01","kind":"sale","planned":true,"acquired":false,"shares":677,"price":225.1983,"value":152459.2491,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $224.5100 to $225.4600. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":45214,"source":{"system":"sec-edgar","filing":"0002001011-26-000083","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000083/edgardoc.xml","form_type":"4"}},{"id":755986,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Common Stock","published_at":"2026-06-02T22:22:18.000Z","date":"2026-06-01","kind":"sale","planned":true,"acquired":false,"shares":491,"price":223.9467,"value":109957.8297,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $223.4250 to $224.3800. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":45891,"source":{"system":"sec-edgar","filing":"0002001011-26-000083","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000083/edgardoc.xml","form_type":"4"}},{"id":755985,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":26867,"kind":"person","name":"Reardon Andrew","position":1,"cik":"0001950232","reported_name":"Reardon Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CLO & Secretary"}}],"security":"Common Stock","published_at":"2026-06-02T22:22:18.000Z","date":"2026-06-01","kind":"exercise","planned":true,"acquired":true,"shares":5000,"price":52.27,"value":261350.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1."}],"balance_after":46382,"source":{"system":"sec-edgar","filing":"0002001011-26-000083","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000083/edgardoc.xml","form_type":"4"}},{"id":760782,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23538,"kind":"person","name":"Espinoza Octavio","position":1,"cik":"0001905248","reported_name":"Espinoza Octavio","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-05-28T23:43:04.000Z","date":"2026-05-27","kind":"exercise","planned":false,"acquired":false,"shares":764,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Grant to reporting person of stock options that will vest and become exercisable over a 4-year period measured from December 5, 2022, with 12-1/2% of the shares subject to the stock options vesting on the date that is six months after December 5, 2022 and the remaining stock options vesting in 42 equal monthly installments thereafter."}],"balance_after":17407,"derivative":{"exercise_price":63.62,"expiration_date":"2032-12-13","underlying":"Common Stock","underlying_shares":764},"source":{"system":"sec-edgar","filing":"0002001011-26-000071","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000071/edgardoc.xml","form_type":"4"}},{"id":760781,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23538,"kind":"person","name":"Espinoza Octavio","position":1,"cik":"0001905248","reported_name":"Espinoza Octavio","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-05-28T23:43:04.000Z","date":"2026-05-27","kind":"exercise","planned":false,"acquired":false,"shares":972,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to approximately 55% of the underlying shares in 12 substantially equal monthly installments beginning on January 5, 2025, and approximately 45% of the underlying shares in two substantially equal monthly installments thereafter."}],"balance_after":0,"derivative":{"exercise_price":52.84,"expiration_date":"2032-05-05","underlying":"Common Stock","underlying_shares":972},"source":{"system":"sec-edgar","filing":"0002001011-26-000071","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000071/edgardoc.xml","form_type":"4"}},{"id":760780,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23538,"kind":"person","name":"Espinoza Octavio","position":1,"cik":"0001905248","reported_name":"Espinoza Octavio","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-05-28T23:43:04.000Z","date":"2026-05-27","kind":"exercise","planned":false,"acquired":true,"shares":972,"price":52.84,"value":51360.48,"ownership":{"direct":true},"balance_after":27679,"source":{"system":"sec-edgar","filing":"0002001011-26-000071","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000071/edgardoc.xml","form_type":"4"}},{"id":760779,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":23538,"kind":"person","name":"Espinoza Octavio","position":1,"cik":"0001905248","reported_name":"Espinoza Octavio","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-05-28T23:43:04.000Z","date":"2026-05-27","kind":"exercise","planned":false,"acquired":true,"shares":764,"price":63.62,"value":48605.68,"ownership":{"direct":true},"balance_after":26707,"source":{"system":"sec-edgar","filing":"0002001011-26-000071","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000071/edgardoc.xml","form_type":"4"}},{"id":779895,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":40267,"kind":"person","name":"KOZARICH JOHN W","position":1,"cik":"0001223000","reported_name":"KOZARICH JOHN W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2026-05-15T01:08:34.000Z","date":"2026-05-13","kind":"exercise","planned":true,"acquired":false,"shares":1575,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"This Option was previously reported as a Grant of 2,329 shares, which vested in full on May 23, 2017, at an exercise price of $119.3000 per share but was adjusted pursuant to the OmniAb Inc. separation from the issuer."}],"balance_after":0,"derivative":{"exercise_price":69.51,"expiration_date":"2026-05-23","underlying":"Common Stock","underlying_shares":1575},"source":{"system":"sec-edgar","filing":"0002001011-26-000049","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000049/edgardoc.xml","form_type":"4"}},{"id":779894,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":40267,"kind":"person","name":"KOZARICH JOHN W","position":1,"cik":"0001223000","reported_name":"KOZARICH JOHN W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2026-05-15T01:08:34.000Z","date":"2026-05-12","kind":"exercise","planned":true,"acquired":false,"shares":459,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"This Option was previously reported as a Grant of 2,329 shares, which vested in full on May 23, 2017, at an exercise price of $119.3000 per share but was adjusted pursuant to the OmniAb Inc. separation from the issuer."}],"balance_after":1575,"derivative":{"exercise_price":69.51,"expiration_date":"2026-05-23","underlying":"Common Stock","underlying_shares":459},"source":{"system":"sec-edgar","filing":"0002001011-26-000049","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000049/edgardoc.xml","form_type":"4"}},{"id":779893,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":40267,"kind":"person","name":"KOZARICH JOHN W","position":1,"cik":"0001223000","reported_name":"KOZARICH JOHN W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-15T01:08:34.000Z","date":"2026-05-13","kind":"sale","planned":true,"acquired":false,"shares":1575,"price":223.5,"value":352012.5,"ownership":{"direct":true},"balance_after":41786,"source":{"system":"sec-edgar","filing":"0002001011-26-000049","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000049/edgardoc.xml","form_type":"4"}}],"next_cursor":"2026-05-15T01:08:34.000000Z,779893"}